132 related articles for article (PubMed ID: 34887657)
1. A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD.
Cowan J; Mulpuru S; Abdallah SJ; Chopra A; Purssell A; McGuinty M; Alvarez GG; Giulivi A; Corrales-Medina V; MacFadden D; Boyle L; Hasimja D; Thavorn K; Mallick R; Aaron SD; Cameron DW
Int J Chron Obstruct Pulmon Dis; 2021; 16():3275-3284. PubMed ID: 34887657
[TBL] [Abstract][Full Text] [Related]
2. Study protocol: a randomized, double-blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations.
Cowan J; Mulpuru S; Aaron S; Alvarez G; Giulivi A; Corrales-Medina V; Thiruganasambandamoorthy V; Thavorn K; Mallick R; Cameron DW
Pilot Feasibility Stud; 2018; 4():135. PubMed ID: 30116551
[TBL] [Abstract][Full Text] [Related]
3. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.
Andreas S; Testa M; Boyer L; Brusselle G; Janssens W; Kerwin E; Papi A; Pek B; Puente-Maestu L; Saralaya D; Watz H; Wilkinson TMA; Casula D; Di Maro G; Lattanzi M; Moraschini L; Schoonbroodt S; Tasciotti A; Arora AK; Maltais F;
Lancet Respir Med; 2022 May; 10(5):435-446. PubMed ID: 35026180
[TBL] [Abstract][Full Text] [Related]
4. Effects of Chinese medicine on patients with acute exacerbations of COPD: study protocol for a randomized controlled trial.
Zhang H; Li J; Yu X; Li S; Wang H; Ruan H; Si Y; Xie Y; Wang M
Trials; 2019 Dec; 20(1):735. PubMed ID: 31842969
[TBL] [Abstract][Full Text] [Related]
5. A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease.
Calverley PMA; Sethi S; Dawson M; Ward CK; Finch DK; Penney M; Newbold P; van der Merwe R
Respir Res; 2017 Aug; 18(1):153. PubMed ID: 28793896
[TBL] [Abstract][Full Text] [Related]
6. General practitioner use of a C-reactive protein point-of-care test to help target antibiotic prescribing in patients with acute exacerbations of chronic obstructive pulmonary disease (the PACE study): study protocol for a randomised controlled trial.
Bates J; Francis NA; White P; Gillespie D; Thomas-Jones E; Breen R; Kirby N; Hood K; Gal M; Phillips R; Naik G; Cals J; Llor C; Melbye H; Wootton M; Riga E; Cochrane A; Howe R; Fitzsimmons D; Sewell B; Alam MF; Butler CC
Trials; 2017 Sep; 18(1):442. PubMed ID: 28969667
[TBL] [Abstract][Full Text] [Related]
7. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
9. Effects of Chinese Herbal Medicine on Acute Exacerbations of COPD: A Randomized, Placebo-Controlled Study.
Li J; Zhang H; Ruan H; Si Y; Sun Z; Liu H; Feng J; Wang Y; Li L; Bai L; Sun H
Int J Chron Obstruct Pulmon Dis; 2020; 15():2901-2912. PubMed ID: 33209019
[TBL] [Abstract][Full Text] [Related]
10. Effect of sequential treatment with syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and "AECOPD Risk-Window": study protocol for a randomized placebo-controlled trial.
Haifeng W; Jiansheng L; Suyun L; Xueqing Y; Hailong Z; Zhiwan W; Qiyi W; Pankui Z; Zhongchao W; Fenglei L; Haihong Y
Trials; 2012 Apr; 13():40. PubMed ID: 22520863
[TBL] [Abstract][Full Text] [Related]
11. The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation.
Cox M; O'Connor C; Biggs K; Hind D; Bortolami O; Franklin M; Collins B; Walters S; Wailoo A; Channell J; Albert P; Freeman U; Bourke S; Steiner M; Miles J; O'Brien T; McWilliams D; Schofield T; O'Reilly J; Hughes R
Health Technol Assess; 2018 Mar; 22(11):1-204. PubMed ID: 29516853
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.
Rabe KF; Celli BR; Wechsler ME; Abdulai RM; Luo X; Boomsma MM; Staudinger H; Horowitz JE; Baras A; Ferreira MA; Ruddy MK; Nivens MC; Amin N; Weinreich DM; Yancopoulos GD; Goulaouic H
Lancet Respir Med; 2021 Nov; 9(11):1288-1298. PubMed ID: 34302758
[TBL] [Abstract][Full Text] [Related]
14. Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial.
Willcox ML; Hu XY; Oliver T; Thorne K; Boxall C; He G; Simpson C; Brotherwood B; O'Neil A; Waugh R; Tilt E; Trill J; Goward N; Francis N; Thomas M; Little P; Wilkinson T; Liu JP; Griffiths G; Moore M
Front Pharmacol; 2023; 14():1221905. PubMed ID: 37818189
[No Abstract] [Full Text] [Related]
15. Aclidinium bromide for stable chronic obstructive pulmonary disease.
Ni H; Soe Z; Moe S
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010509. PubMed ID: 25234126
[TBL] [Abstract][Full Text] [Related]
16. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
Cowan J; Gaudet L; Mulpuru S; Corrales-Medina V; Hawken S; Cameron C; Aaron SD; Cameron DW
PLoS One; 2015; 10(11):e0142205. PubMed ID: 26558756
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study protocol for a randomized controlled trial.
Xie S; Yan P; Yao C; Yan X; Huo Y; Zhang J; Liu S; Feng Z; Shang H; Xie L
Trials; 2019 Feb; 20(1):136. PubMed ID: 30777117
[TBL] [Abstract][Full Text] [Related]
19. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Kew KM; Mavergames C; Walters JA
Cochrane Database Syst Rev; 2013 Oct; (10):CD010177. PubMed ID: 24127118
[TBL] [Abstract][Full Text] [Related]
20. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
